PR Newswire BiotechOriginal article
Skyhawk Therapeutics gibt die endgültigen Ergebnisse nach 15 Monaten aus der klinischen Phase-1/2-Studie mit SKY-0515 bei Patienten mit Huntington-Krankheit bekannt
Data ReadoutpositiveSKY-0515Positive
AI Analysis
Summary
Skyhawk Therapeutics announced final 15-month Phase 1/2 clinical trial results for SKY-0515 in Huntington's disease patients, meeting primary endpoints with treated patients showing benefit versus external control group.
Clinical Trial Data
Phase
1/2
Primary Endpoint
Met
Outcome Details
15-month final Phase 1/2 data shows SKY-0515 treated patients demonstrated benefit compared to external control group at primary endpoint
Importance:6/10
Sentiment:
0.70
Huntington's diseasePhase 1/2Clinical dataSKY-0515
Read the original article
Published by PR Newswire Biotech on September 16, 2026 8:37 PM